IL15 and neoplasm: Based on target cell expansion (CD8+ or CD4+ effector memory T cells) in tumor and peripheral blood (data not shown), 0.01 mg/kg of PD1/IL15 TaCk was identified as mPAD in a humanized (hCD34+ engrafted in NSG) mouse model.